BioNTech and OncoC4 shared positive survival data from a late-stage trial of their drug candidate in lung cancer that was previously hit with a partial hold by the FDA. The biotech’s treatment, called gotistobart, slashed …
Cogent’s mastocytosis drug continues momentum, helps treat sicker patients
Cogent Biosciences said its mastocytosis drug helped patients with an advanced form of the blood disease, building on successful data reported over the summer and teeing up a regulatory submission in 2026. In the Phase …
Day One was one of three parties interested in Mersana; Bihua Chen and Cormorant’s third SPAC
Plus, news about Bicara Therapeutics, Boehringer Ingelheim, Gubra, AbbVie, OSE Immunotherapeutics, Encoded Therapeutics, UCB and Immix Biopharma: 🤝 Two other companies were interested in Mersana: Day One wasn’t the only company to submit offers …
#ASH25: Kura, Syndax detail data for rival menin inhibitors as both eye earlier use in AML
Kura Oncology and Kyowa Kirin said 73% of newly-diagnosed patients with certain forms of acute myeloid leukemia had a complete response after receiving their oral menin inhibitor. The early-stage results stoke their rivalry with Syndax …
Exploring a Digital Health Solution to Collect and Manage Health-Related Needs for Patients Who Undergo Complex Surgery: Mixed Methods Study
Background: Patients who undergo complex surgery (e.g., esophagectomy, liver resection) often experience substantial burden of health-related needs (medical, social, and behavioral health). A closed loop digital solution could facilitate the collection and resolution of health-related needs by care team members for patients who undergo complex surgery. A digital solution may facilitate adherence to a clear […]
Merck outbid three competitors in Cidara acquisition — new filing
Cidara Therapeutics commanded a highly competitive bidding war for its influenza antiviral, attracting acquisition proposals from four pharmaceutical companies, according to a Friday evening regulatory filing. Merck offered nearly 20% more …
Structure Therapeutics’ obesity pill stacks up with Novo and Lilly; Ascletis also reports early results
Structure Therapeutics’ GLP-1 pill cut patients’ body weight by a placebo-adjusted average of 11.3% at around eight and a half months. This is competitive with both Eli Lilly’s orforglipron and Novo Nordisk’s oral formulation of …
First volunteer receives Lassa fever vaccine in University of Oxford trial
The first human has been vaccinated with Oxford’s new Lassa fever vaccine in a major first‑in‑human trial The first volunteer has received a dose of the experimental Lassa fever vaccine as part of a first‑in‑human trial at the University of Oxford, a landmark moment in the fight against a deadly virus for which no licensed […]
ASH: Gilead preps filing for anito-cel on iMMagine-1 data
Gilead’s Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate anito-cel, which could launch next year.
Mirum to pay $620M for Bluejay and its hepatitis D antibody
Mirum Pharmaceuticals will acquire Bluejay Therapeutics for $620 million upfront to gain access to a late-stage chronic hepatitis D treatment. Mirum believes the drug, a monoclonal antibody called brelovitug that’s in Phase …